Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Synthetic Biologics, Inc. (SYN) Starts Presentation at the OneMedForum 2013 Conference

Synthetic Biologics is a biotechnology company developing product candidates for serious infections and diseases. The company is developing a biologic for preventing C. diff infection as well as a series of monoclonal antibodies (mAbs) for treating serious infectious diseases. In collaboration with Intrexon, Synthetic Biologics is developing a synthetic DNA-based therapy for treating pulmonary arterial hypertension (PAH). The company is also developing treatments for relapsing-remitting multiple sclerosis, cognitive dysfunction in MS and amyotrophic lateral sclerosis. For more information, visit the company’s Web site at www.syntheticbiologics.com.

The 6th Annual OneMedForum is a gathering of leading investors and management of some of the most promising emerging life science companies in Asia and North America. Through panels, workshops and up-close programming with top industry leaders, attendees explore strategies for company growth finance with healthcare investors looking for outsized returns. For more information, please visit www.onemedforum.com.

Let us hear your thoughts below:

This entry was posted in OneMedForum Conference. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *